It s developing neural interface technology a.k.a. putting microchips into people s brains.
The technology could help study and treat neurological disorders.
Tesla billionaire Elon Musk is known for high-profile companies like Tesla and SpaceX, but the billionaire also has a handful of unusual ventures. One them, he says, he started to one day achieve symbiosis between the human brain and artificial intelligence.
Neuralink is Musk s neural interface technology company. Simply put, it is building technology that could be embedded in a person s brain, where it could both record brain activity and potentially stimulate it.
While Musk likes to talk up his futuristic vision for the technology, merging human consciousness with AI, the tech has plenty of near-term potential medical applications such as the treatment of Parkinson s disease.
Neurological disorders are the leading cause of disability-adjusted-life-years and the second leading cause of death globally. Despite the global burden.
E-Mail
IMAGE: A schematic overview of the study design. AD = Alzheimer s disease; ADNI = Alzheimer s disease Neuroimaging Initiative; ADSP = Alzheimer s disease Sequencing Project; cis-GReX = cis-genetically regulated expression; FOCUS =. view more
Credit: Liu N, et al., 2021, PLOS Genetics
A research team led by Chunshui Yu and Mulin Jun Li of Tianjin Medical University has discovered two new genes potentially involved in Alzheimer s disease. They identified them by exploring which genes were turned on and off in the hippocampus of people who suffered from the disease. The team s new findings are published February 25th in
PLOS Genetics.
Alzheimer s disease is a neurodegenerative disorder that involves worsening dementia and the formation of protein plaques and tangles in the brain. The hippocampus, part of the brain involved in memory, is one of the first regions to sustain damage. To better understand which genes contribute to the progression of this heritabl
Researchers probe deeper into the neuronal mechanisms underlying olfactory dysfunction in Alzheimer’s
Loss of smell or olfactory dysfunction is an early indication of the neurodegenerative Alzheimer s disease (AD) and appears in approximately 90% of all patients. While loss of smell is a major symptom, patients with AD are only unable to recognize specific odors and do not completely lose their sense of smell; this suggests a possible region-specific involvement of the olfactive center in the brain.
Amyloid β (Aβ), a toxic protein that accumulates in the brain is a known contributing factor in AD pathogenesis and is also present in the olfactory system that controls the sense of smell. However, the pathology and mechanisms of AD-specific olfactory dysfunction involving olfactory sensory neurons (OSNs) remain unclear.